New England Investment Retirement Group Exits Position in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : New England Investment Retirement Group has sold out all of its stake in Eli Lilly and Co during the most recent quarter, according to the disclosure filed by the company on Aug 1, 2016 with the SEC. The investment management company has sold out 32,049 shares of Eli Lilly and Co which is valued at $2,651,093.

Other Hedge Funds, Including , South Texas Money Management Ltd sold out all of its stake in LLY during the most recent quarter. The investment firm sold 7,163 shares of LLY which is valued $592,523. Stoneridge Investment Partners added LLY to its portfolio by purchasing 2,953 company shares during the most recent quarter which is valued at $246,280. Eli Lilly and Co makes up approx 0.03% of Stoneridge Investment Partners’s portfolio. Seven Bridges Advisors added LLY to its portfolio by purchasing 6,960 company shares during the most recent quarter which is valued at $580,464. Eli Lilly and Co makes up approx 0.48% of Seven Bridges Advisors’s portfolio.Gateway Investment Advisers reduced its stake in LLY by selling 13,542 shares or 1.79% in the most recent quarter. The Hedge Fund company now holds 743,920 shares of LLY which is valued at $59,037,491. Eli Lilly and Co makes up approx 0.49% of Gateway Investment Advisers’s portfolio.

Eli Lilly and Co closed down -0.3 points or -0.36% at $82.42 with 20,93,793 shares getting traded on Thursday. Post opening the session at $83.02, the shares hit an intraday low of $82.37 and an intraday high of $83.02 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *